EMEA-002369-PIP01-18-M02
Key facts
| Active substance |
idecabtagene vicleucel
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0068/2021
|
| PIP number |
EMEA-002369-PIP01-18-M02
|
| Pharmaceutical form(s) |
Dispersion for injection
|
| Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Celgene Europe B.V.
Tel. +41 327298500 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|